Plk1 inhibitors were equally effective at inhibiting Plk1 in mesenchymal/sensitive and epithelial/resistant NSCLC cell lines (Ferrarotto et al, 2016). The gene discussed is PLK1; the disease is non-small cell lung carcinoma.